Industry News
Biotechnology Industry News
The show is over for Pulmocide’s…
The show is over for Pulmocide’s phase 3 trial after patients given its investigational inhaled antifungal had lower response rates and a higher chance of death than patients in the control arm.
Amgen is getting down with Disco…
Amgen is getting down with Disco Pharmaceuticals, commissioning the German outfit to work on cancer therapies focused on a target the biotech has already identified.
Rakuten Medical has added to its…
Rakuten Medical has added to its tally of mega-rounds, pocketing another $100 million to push its lead light-based cancer therapy toward a targeted FDA approval filing in 2028.
Soley Therapeutics has secured…
Soley Therapeutics has secured $200 million in series C funds, which the AI-enabled biotech plans to use to take its lead acute myeloid leukemia asset into the clinic.
Basilea Pharmaceutica is…
Basilea Pharmaceutica is continuing its quest to develop much-needed new antifungal drugs by penning a deal with Prokaryotics worth at least $48 million.
GSK’s potential “functional…
GSK’s potential “functional cure” for hepatitis B drug has proven its worth in a pair of hotly anticipated phase 3 studies, setting up the pharma for a push to the FDA.
A phase 3 trial of Hutchmed’s…
A phase 3 trial of Hutchmed’s autoimmune disease candidate sovleplenib has hit its primary endpoint, delivering a boost to an asset that was held up by quality issues in another indication.
Alveus Therapeutics, which…
Alveus Therapeutics, which launched Thursday under the stewardship of former I-Mab CEO Raj Kannan, is hoping its development candidates can overcome pitfalls common to existing obesity medicines.
Bright Minds Biosciences has…
Bright Minds Biosciences has debuted glowing phase 2 results for its lead anti-seizure asset, giving the biotech’s stock a jolt and setting up future registrational trials for the serotonin receptor agonist.
Boehringer Ingelheim has unveiled…
Boehringer Ingelheim has unveiled its second kidney-focused collaboration in recent weeks, this time penning a deal worth potentially $120 million with genomics-focused Variant Bio.
Amgen is adding Dark Blue to its…
Amgen is adding Dark Blue to its tapestry, embedding the U.K. biotech’s preclinical blood cancer program into its organization.
In a strategic move that could…
In a strategic move that could protect its obesity pipeline from future patent litigation, Roche is paying $100 million to secure a license from Structure Therapeutics.
Eli Lilly has returned to Nimbus…
Eli Lilly has returned to Nimbus Therapeutics for another metabolic collaboration, this time focused on the red-hot space of oral obesity therapies.
A pair of phase 3 psoriasis…
A pair of phase 3 psoriasis studies of Alumis’ TYK2 inhibitor have hit their primary endpoints, setting the biotech up to file for approval of a potential challenger to Bristol Myers Squibb’s Sotyktu. With the
Instil Bio’s hopes for its…
Instil Bio’s hopes for its refreshed clinical pipeline appear to have ended in failure, with the U.S. biotech handing the rights to two drugs back to their original owner.
U.K. biotech Ikarovec has teamed…
U.K. biotech Ikarovec has teamed up with VectorBuilder to work on an eye disease gene therapy that could be administered in a doctor’s office.
Less than two weeks after…
Less than two weeks after rejecting Sanofi’s investigational multiple sclerosis drug, the FDA has publicly shared the complete response letter, citing both efficacy and safety concerns, including a case of serious liver injury that led
Pfizer is penning a cancer…
Pfizer is penning a cancer discovery pact with Cartography Biosciences that could max out at $865 million biobucks.
Gilead Sciences has found a shiny…
Gilead Sciences has found a shiny new package for one of its cancer assets, inking an up to $300 million research pact for access to OncoNano Medicine’s tumor-targeting lipid particles.
MetaVia has shared an update on…
MetaVia has shared an update on its attempt to crash the obesity party, reporting average weight loss of 9.1% in people who received its dual agonist of GLP-1 and glucagon in a phase 1 trial.